These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8764084)

  • 21. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
    Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
    Kamkamidze G; Sullivan T; Charbonneau T
    J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient.
    de Ronde A; van Dooren M; de Rooij E; van Gemen B; Lange J; Goudsmit J
    AIDS; 2000 Nov; 14(16):2632-3. PubMed ID: 11101087
    [No Abstract]   [Full Text] [Related]  

  • 24. High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.
    Imamichi T; Sinha T; Imamichi H; Zhang YM; Metcalf JA; Falloon J; Lane HC
    J Virol; 2000 Jan; 74(2):1023-8. PubMed ID: 10623768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.
    Imamichi T; Berg SC; Imamichi H; Lopez JC; Metcalf JA; Falloon J; Lane HC
    J Virol; 2000 Dec; 74(23):10958-64. PubMed ID: 11069990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
    Lennerstrand J; Hertogs K; Stammers DK; Larder BA
    J Virol; 2001 Aug; 75(15):7202-5. PubMed ID: 11435603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children.
    Palomares JC; Perea EJ; Terrero E; Torres MJ; García ML; Romero J; Alejo A
    Clin Microbiol Infect; 2000 May; 6(5):268-70. PubMed ID: 11168125
    [No Abstract]   [Full Text] [Related]  

  • 31. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse transcriptase fidelity and HIV-1 variation.
    Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
    Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
    [No Abstract]   [Full Text] [Related]  

  • 35. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
    Paintsil E; Margolis A; Collins JA; Alexander L
    J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.
    Shafer RW; Winters MA; Jellinger RM; Merigan TC
    J Infect Dis; 1996 Aug; 174(2):448-9. PubMed ID: 8699089
    [No Abstract]   [Full Text] [Related]  

  • 39. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
    Kellam P; Boucher CA; Larder BA
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1934-8. PubMed ID: 1371886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL; Das K; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.